Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Not a single study

Story checked

Common asthma drug improves strength in children with muscle disease (opens in a new tab)

news-medical.net · 2026-10-14

Short answerEvidenceSource

Short answer

Not a single study

No clear answer.

The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

This story isn't reporting one study.

The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.

Open claim evidence
3

Search result

No single source study.

The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.

Related research

Research nearby

Research on this topic

Nearby papers when the source is unclear.

and 11 more considered

Then inspect each claim

Evidence layer

Claim by claim

What the story asserts. With no source study, there is nothing to check these against.

Claim 1 of 7Not checkedA common asthma medication improved motor skills and muscle strength in children with congenital myopathies.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 2 of 7Not checkedIn the study, children receiving the drug were able to walk and stand up more quickly.View evidenceHide evidence

As statedwalked 38 meters farther in six minutes and stood up about 1.9 seconds faster on average

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 3 of 7Not checkedThe study included 18 people aged 6 to 16 with genetically confirmed congenital myopathy, who were randomized to salbutamol plus usual treatment or usual treatment alone for 24 weeks before switching treatments.View evidenceHide evidence

As stated18 participants; 24 weeks

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 4 of 7Not checkedAfter salbutamol treatment, average motor function on the MFM-32 was 3.61 points better than with standard treatment alone.View evidenceHide evidence

As stated3.61 points on MFM-32

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 5 of 7Not checkedGrip strength in the dominant hand increased by about 1.5 kilograms during salbutamol treatment, and forced vital capacity was about 0.2 liters higher.View evidenceHide evidence

As stated~1.5 kg grip strength; ~0.2 L forced vital capacity

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 6 of 7Not checkedThe treatment was well tolerated, and no serious side effects were reported.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 7 of 7Not checkedThe researchers said the results suggest oral salbutamol could become a symptom-relieving treatment option in the future, but larger international studies are needed.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Finally, the search trail

Method layer

No single source study was found.

NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.

Nearby research

No exact source, but these papers are close.

PubMed, Crossref, Europe PMC · 15 candidate papers

And 10 more candidates considered.